The efficacy of narrowband ultraviolet B phototherapy combination with tofacitinib in the treatment of vitiligo: a randomized controlled trial
Background This randomized control clinical trial aimed to evaluate the efficacy of tofacitinib combined with phototherapy narrowband ultraviolet B (UVB) in the treatment of vitiligo.Methods A total of 136 vitiligo patients were randomized to UVB treatment (UVB group) or UVB treatment combined with...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2479567 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background This randomized control clinical trial aimed to evaluate the efficacy of tofacitinib combined with phototherapy narrowband ultraviolet B (UVB) in the treatment of vitiligo.Methods A total of 136 vitiligo patients were randomized to UVB treatment (UVB group) or UVB treatment combined with tofacitinib (TOF-UVB group). The patients were followed up for 24 weeks. In post-treatment analysis of treatment outcomes, the vitiligo area severity index (VASI) and dermatology life quality index (DLQI) were measured. Serum levels of inflammatory factors including IL-17, IL-23, IFN-γ and IL-6, were measured with enzyme-linked immunosorbent assay.Results In post-treatment analysis, significantly more patients in the TOF-UVB group (n = 63) showed effective recovery compared to the UVB group (n = 61). TOF-UVB group also demonstrated markedly lower VASI and DLQI scores than the UVB group. Pronouncedly lower levels of inflammatory factors were also observed.Conclusions Our data suggest that UVB-TOF is potentially more effective than UVB alone in promoting recovery of vitiligo patients and reducing inflammatory factors. |
|---|---|
| ISSN: | 0954-6634 1471-1753 |